NASDAQ: CRDL - Cardiol Therapeutics Inc.

Yield per half year: -31.77%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Cardiol Therapeutics Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx for patients hospitalized with COVID-19, as well as for the treatment of recurrent pericarditis and acute myocarditis.

more details
The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure. Cardiol Therapeutics Inc. was incorporated in 2017 and is headquartered in Oakville, Canada.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2019-01-15
ISIN CA14161Y2006
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cad
Сайт https://www.cardiolrx.com
Цена ао 1.95
Change price per day: -0.7576% (1.32)
Change price per week: +2.34% (1.28)
Change price per month: -17.09% (1.58)
Change price per 3 month: -36.71% (2.07)
Change price per half year: -31.77% (1.92)
Change price per year: +55.4% (0.843)
Change price per 3 year: -32.82% (1.95)
Change price per 5 year: -55.58% (2.949)
Change price per 10 year: 0% (1.31)
Change price per year to date: -33.16% (1.96)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 2.51 6
P/E 0 0
EV/EBITDA -1.23 0
Total: 3.25

Efficiency

Title Value Grade
ROA, % -76.64 0
ROE, % -99.58 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.0059 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 120.28 10
Yield EPS, % 6.4 1
Total: 4.2
More

Institutions Volume Share, %
MMCAP International, Inc. SPC 2953300 4.33
AdvisorShares Investments, LLC 1189978 1.75
Tejara Capital Ltd 1116676 1.64
AXS Investments, LLC 697651 1.02
Lion Street Advisors, LLC 192700 0.28
Bank of Montreal/Can/ 104479 0.15
We Are One Seven, LLC 100000 0.15
Laird Norton Trust Company, LLC 100000 0.15
Cambridge Investment Research Advisors Inc. 85201 0.12
Credit Suisse Ag/ 80000 0.12

ETF Share, % Profitability for 1 year, % Dividends, %
AdvisorShares Pure Cannabis ETF 6.51027 -3.73 1.68573



Head Job title Payment Year of birth
Mr. David G. Elsley MBA President, CEO & Director 550.14k
Mr. Christopher J. Waddick C.A., C.M.A., CPA, CMA, MBA CFO, Corporate Secretary & Director 216.79k
Mr. Bernard Lim B.Sc. Chief Operating Officer 379.39k
Dr. Andrew Warwick Hamer M.D. Chief Medical Officer & Head of Research & Development 549.01k 1962 (63 years)
Trevor Burns Investor Relations N/A
Mr. John A. Geddes BSCPT, MBA Vice President of Corporate Development

Address: Canada, Oakville, 2265 Upper Middle Road East - open in Google maps, open in Yandex maps
Website: https://www.cardiolrx.com